Skip to main content
. 2021 Oct 25;35(1):360–378. doi: 10.1007/s13577-021-00636-7

Fig. 1.

Fig. 1

Expression levels of USP30-AS1 and its promoter methylation sites in AML. A1 Global expression of lncRNA USP30-AS1 across 31 cancer types. A2 Expression levels of USP30-AS1 between the normal and LAML tumor tissues. *p < 0.05, Tumor tissues: n = 173; Normal tissues: n = 70. B Overall survival analysis between AML patients with low and high expression of USP30-AS1. C Effects of low- and high-methylation status across diverse methylation sites of USP30-AS1 promoter on survival in AML patients. *p < 0.05, n = 60. D Correlation analysis of expression of USP30-AS1 and different methylation status of promoter